Evidence map›Paper›PMID 36084423›Full record

ArticleDiagnostic microbiology and infectious disease2022

Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay.

Scott J C Pallett, Michael Rayment, Joseph Heskin, Andrea Mazzella, Rachael Jones, Nabeela Mughal, Paul Randell, Gary W Davies, Luke S P Moore

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic microbiology and infectious disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Scott J C PallettCentre of Defence Pathology, Royal Centre for Defence Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK; Clinical Infection Department, Chelsea and Westminster NHS Foundation Trust, London, UK. Electronic address: scott.pallett@nhs.net.
Michael RaymentClinical Infection Department, Chelsea and Westminster NHS Foundation Trust, London, UK.
Joseph HeskinClinical Infection Department, Chelsea and Westminster NHS Foundation Trust, London, UK.
Andrea MazzellaClinical Academic Group, Institute for Infection and Immunity, St George's University of London, London, UK.
Rachael JonesClinical Infection Department, Chelsea and Westminster NHS Foundation Trust, London, UK.
Nabeela MughalClinical Infection Department, Chelsea and Westminster NHS Foundation Trust, London, UK; Imperial College Healthcare NHS Trust, North West London Pathology, London, UK.
Paul RandellClinical Academic Group, Institute for Infection and Immunity, St George's University of London, London, UK.
Gary W DaviesClinical Infection Department, Chelsea and Westminster NHS Foundation Trust, London, UK.
Luke S P MooreClinical Infection Department, Chelsea and Westminster NHS Foundation Trust, London, UK; Imperial College Healthcare NHS Trust, North West London Pathology, London, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections & Antimicrobial Resistance, Imperial College London, London. UK.
Chelsea and Westminster Hospital NHS Foundation Trust · GBImperial College Healthcare NHS Trust · GBSt George's, University of London · GBUniversity of Ulster · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection or vaccination, but concern exists around ability to make timely assessment of immune status of community-based patients where laboratory-based serodiagnostics predominate. Participants were invited to undergo paired laboratory-based (Abbott Architect SARS-CoV-2 IgG Quant II chemiluminescent microparticle immunoassay) and lateral flow assays (LFA; a split SARS-CoV-2 IgM/IgG and total antibody test) able to detect SARS-CoV-2 anti-spike antibodies. LFA band strength was compared with CMIA titer by log-linear regression. Two hundred individuals (median age 43.5 years, IQR 30-59; 60.5% female) underwent testing, with a further 100 control sera tested. Both LFA band strengths correlated strongly with CMIA antibody titers (P < 0.001). LFAs have the potential to assist in early identification of seronegative patients who may demonstrate the greatest benefit from monoclonal antibody treatment.

Indexed as

COVID-19COVID-19 Drug TreatmentSARS-CoV-2AdultAntibodies, MonoclonalAntibodies, ViralFemaleHumansImmunoglobulin GImmunoglobulin MMaleAntibodies, MonoclonalAntibodies, ViralImmunoglobulin GImmunoglobulin MCOVID-19Lateral flow assayMonoclonal antibody

Identifiers

PMID36084423
PMCPMC9371766
OpenAlexW4290999120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.